Journal
LEUKEMIA & LYMPHOMA
Volume 52, Issue 6, Pages 1024-1029Publisher
INFORMA HEALTHCARE
DOI: 10.3109/10428194.2011.563885
Keywords
Chronic myeloid leukemia; imatinib; trough blood level; cytogenetic response; molecular response
Categories
Ask authors/readers for more resources
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or molecular responses, we measured trough IM levels in patients with chronic myeloid leukemia, chronic phase (CML-CP), at 6 months of treatment with a standard dose of IM. Eighty-seven newly diagnosed patients with CML-CP were prospectively enrolled. Seventy-eight patients (89.7%) showed an optimal response (complete or partial cytogenetic response) at 6 months. Trough IM levels were 1378 +/- 725 ng/mL. When categorized into two groups, there was a statistically significant difference in numbers of patients with optimal and suboptimal responses at 6 months (group with < 1000: 80.6% vs. 19.4%; >= 1000: 94.6% vs. 5.4%; p=0.032), and in numbers of patients with early major molecular response (early-MMR) and without MMR at 6 months (group with < 1000: 3.2% vs. 96.8%; >= 1000: 21.4% vs. 78.6%; p=0.047). In conclusion, the incidence of optimal cytogenetic response or early-MMR in patients with CML-CP treated with IM for 6 months was significantly higher in those with a trough level of >= 1000 compared with those with a level of < 1000. Dose escalation of IM can be one option in patients with CML showing suboptimal response or resistance to the standard dose of IM, especially with low trough plasma IM levels (< 1000 ng/mL).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available